CD86

Across TCGA pan-cancer cohorts, CD86 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CD86 data layer compared with 17 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CD86 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD86 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LIHC, BLCA, and LUSC are the cancer types where CD86 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.165	0.779	<.001	18	view →
BLCA	DFS	Median	All	0.507	0.594	<.001	15	view →
LUSC	OS	Median	All	0.166	0.660	.002	12	view →
UCEC	OS	Median	II,III,IV	1.000	0.840	.038	8	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
SKCM	DFS	Median	III,IV	0.805	0.462	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CD86–LIHC (OS)

Open the LIHC breakdown →